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Abstract 
Arterial hypertension Osteoarthritis and their coincidence, as proven, may have benefit from omega-3-
polyunsaturated acids implication. Adipokines (leptin and adiponectin) levels are investigated and 
compared depending on body mass index in patients with mentioned pathology; dynamics of values 
investigated under influence of omega-3-polyunsaturated acids implication. Established, that omega-3 
fatty acid supplementation has potential of restoring of natural balance of adipokines (leptin, adiponectin) 
and mild lipid-lowering action in obese patients with arterial hypertension, osteoarthritis and their 
combination, so, seems to be useful in therapeutic patterns for mentioned diseases. Exact mechanisms, 
dosage and longer duration of therapy may be promising subject for further investigation. 
 




Recent studies have clearly shown the importance of polyunsaturated fatty acids (as essential 
fatty acids) and their nutritional value for human health.  
On the basis of the pleiotropic signaling actions of electrophilic fatty acids and the apparent 
safety of many electrophilic FDA-approved drugs, the potential benefits of the in vivo 
administration of these reactive lipid mediators have been evaluated in a plethora of murine 
models of disease. ω-3 PUFA can inhibit the production of these inflammatory cytokines such 
as IL-1, IL-6, and TNF-α, which provide an important stimulus for osteoclastic bone 
resorption, and suppression of the production of these cytokines by ω-3 PUFA may inhibit 
bone resorption and prevent bone loss [1, 2]. 
Diseases or pathologies that are discussed as those which may have benefit from omega-3-
polyunsaturated acids implication include (but are not limited by) diabetes and metabolic 
syndrome, nephropathy, ischemia-reperfusion injury, cardiovascular diseases and arterial 
hypertension in partial, pulmonary inflammation, and chronic inflammatory disorders. With 
the rising epidemic of obesity, more efficacious therapeutic strategies are needed to address the 
complex pathophysiological events that lead to metabolic syndrome. 
 
2. Materials and Methods  
100 patients were examined, 35 – with primary arterial hypertension (AH), 35 – with 
osteoarthritis (ОА) and 30 – with AH + coinciding OA among them> All pateoints underwent 
stationary treatment in cardiological and/or rheumatological depts. Of State communal 
Establishment “City Clinical Hospital #3” during 2013-2014 years period. Female: male” ratio 
was 2, 5:1, average age – 49, 6 ± 8, 9 tears. Average duration of AH was 4-12 years (averagely 
7,4±3,8 years), and corresponded 2nd stage (ECG-signs of mild to moderate hypertrophy of left 
ventricle – in 100% cases, specific changes of eye fundus – in ophthalmoscopy – in 96,6%). 
Duration of OA was 8, 4 ± 4, 6 years. ОА was diagnosed using criteria of American 
Rheumatological Association. Patients with affliction of big joints of lower extremities were 
prevalent among examined subjects (35% - hip joints arthritis, 60% - knee joint affliction) and 
hand joints. According to X-ray data, all patients corresponded 2-3rd stages of OA by Kellgren-
Lawrence, and everybody included into investigation had no synyitis symptoms (by clinical 
data). All procedures were approved by Local Ethic Committee, performed after written 
concent obtaining and corresponded to GCP requirements.  
Control measurements were performed in healthy subjects group (n = 22), who had no signs of 
exacerbation of any chronic pathology or acute diseases including respiratory during minimally 
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3-months period. Control group corresponded to clinical 
groups by age, gender ratio and body mass index (BMI). 
Anthropometry – weight and height – was done on same day 
with blood collection using metrologically controlled devises. 
Body mass index (BMI) was calculated using standard 
formula.  
Blood for biochemical measurements and adipokines level 
detection was collected on 1st or 2nd day of patients in hospital, 
in same time (around 9-10 a.m.), in fasting state, at least 12 
hours after last meals intake. Heavy physical loading, alcohol 
intake and fatty food vere prohibited during 24 hours before 
blood testing.  
Leptin and adiponectin blood content were measured 
employing ELISA test which use of Assaypro diagnostic kit 
over certified analyser. Biochemical tests were performed in 
Central Diagnostic Center of Chernivtsi Region on 
biochemical analyser «Accent 200» («Cormay S.A.», Poland). 
All patients depending on nosology were prescribed standard 
basic therapy which included: ACE inhibitors (lisinopril), 
beta-blockers (bisoprolol) in AH, non-steriodal anti-
inflammatory remedies (meloxicam, ibuprofen, diclofenak 
sodium) + chondroprotectors (chondroitin sulphate) in OA. 
Patients demonstrating dyslipidemia were distributed 
randomly to 2 subgroups: those obtaining statins (rosuvastatin) 
only (comparation group) and principal group who got omega-
3-polyunsaturated acids as addition to standard therapy 
(Epadol-Neo, produced by Kyiv Vitamine Factory, registry 
number UA/9124/01/01 dated 27.11.2008; order № 684 dated 
27.11.2008)/ Epadol-Neo includes eicosapentaenoic acid (300 
mg), docosahexaenoic acid (200 mg), other fatty acids - 498 
mg, d-α-tocoferol (2 mg) it was taken by patients in QD 
regimen, 2 caps per intake during 2 months.  
Results were mathematically proceeded and statistically 
approved employing variants statistical analysis over РС 
Реntium ІІІ. 
 
3. Obtained results  
Analysis of leptin content in blood serum of healthy people 
revealed mild statistically not supported trend to dependence 
from BMI, and values of leptin in both people with optimal 
and increased BMI remained within average for population, 
determined as normal by analytical set producers (1,1 - 27,6 
ng/ml) (рiс. 1).  
Leptin level in OA patients demonstrated great differences 
depending on BMI. Those with increased weight had 
significantly higher leptin levels comparing optimal BMI 
group (40,5±4,3 vs 16,38±4,87, ng/ml). Around 30% of 
patients with optimal BMI and 90% - with increased BMI 
demonstrated increased total cholesterol concentration. Similar 
trend was observed in patients with AH: much higher 
statistically significant leptin levels in obese representatives 
(17,9 ±4,36 vs 49,3±5,48 ng/ml, (p<0,05)), and in those with 
coincidence of OA and AH (33,0±4,94 vs 55,4±4,62 ng/ml, 
(p<0,05)), pic.1. 83% patients with AH and 100% - with OA 





Pic.1: Leptin level in blood of patients before and after treatment (standard therapy and Epadol-Neo). 
 
We observed no significant differences of adiponectin 
concentration in serum of healthy people with different BMI. 
Same finding was remarkable for other investigated groups: 
average concentration remained similar to same in healthy 
ones in patients with both OA and AH (24,0±2,1 vs 28,1±3,1 
ng/ml (p<0,05) for healthy persons with increased and optimal 
BMI; 33,8±3,42 in subjects with AH and 22,1±3,11 in patients 
with OA). Increase of BMI in both subgroups was 
accompanied with statistically significant decrease of 
adiponectin concentration - 14, 6±2, 91 ng/ml in obese OA 
patients and 18, 1±1, 52 ng/ml in obese AH patients. Co-
incidence of AH and OA lead to dramatic decrease of 
adiponectin concentration– 12, 3±2, 02 and 13, 3±2, 21 ng/ml 
(p<0,05) in subjects with optimal and increased BMI.  
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Pic. 2: Adiponectin levels in patients before and after treatment (standard therapy and Epadol-Neo). 
 
Treatment had different influence over adipokines level in 
blood on patients with AH, OA and their coincidence. So, 
comparative treatment based on standard medications caused 
no influence (see pic.1) over both adipokines levels. 
Additional implication of Epadol–Neo containing omega-3-
unsaturated fatty acids markedly significantly decreased leptin 
content in obese patients with AH: from 49,3±5,48 ng/ml to 
16,5±1,73 ng/ml (p<0,05), final value returned to normal 
range. Less dynamics, but as well proven statistically was 
observed in OA and combination of OA and AH: decrease of 
blood concentration of leptin from 40,5±4,3 to 34,3±3,43 
ng/ml (p<0,05) and from 55,4±4,62 ng/ml to 38,2±7,61 ng/ml 
(p<0,05) .  
Adiponectin levels were more sensitive to treatment. Ositive 
statistically approved changes were observed in comparative 
group patients with all investigated pathologies (isolated OA, 
AH and their coincidence) after 2 months of administration of 
standard therapy. Additional prescription of Epadol–Neo 
containing omega-3-unsaturated fatty acids lead to further 
improvement of adiponectin level, but difference with 
comparative group was not proven statistically (pic.2).  
Standard treatment of principal disorders improved partially 
dyslipidemia changes in observed groups (pic.3), so on first 
glance seemed to be quite effective. So, total cholesterol level 
decreased from 5,8±0,41 to 4,7±0,32 mmol/l (p<0,05) in 
comparative group obtaining statins only, difference confirmed 
statistically. Implication of Epadol-Neo lead to further 
improvement (4.4±0,22 mmol/l) in principal group. Same 
positive dynamics was observed for rest indices – HDL level 
increased after treatment from 1,5±0,12 to 1,6±0,11 mmol/l in 
comparative group and to 1,73±0,13 (p<0,05) in principal 
groups; triglycerides content both in comparative and principal 
groups returned to normal values: 2,2±0,14 mmol/l before 
treatment; 1,8±0,09 mmol/l (p<0,05) and 1,7±0,07 mmol/l 




Pic. 3: Lipidogram values dynamics under influence of hypolipidemic treatment – with and without polyunsaturated fatty acids. 
 
4. Discussion  
Obesity is increasing in the Western society, and obesity-
linked complications are under intense scrutiny. Among these, 
not only metabolic disorders, such as diabetes mellitus and 
dyslipidemia, but also cardiovascular disorders, such as 
hypertension and ischemic heart diseases, have been shown to 
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be associated with obesity [1, 2]. More recently, also chronic 
diseases in which inflammation plays a role such as 
osteoarthritis, rheumatoid arthritis, inflammatory bowel 
disease, chronic obstructive pulmonary disease, and asthma 
have been associated with obesity [5-7]. 
The adipose tissue consists of adipocytes and the stromal 
vascular fraction, in which a variety of immune cells can be 
found. Among these, macrophages and T-cells are the most 
abundant [1, 8]. Expansion of the adipose tissue is accompanied 
by an increased infiltration of immune cells with a pro-
inflammatory phenotype. The cross-talk between the 
infiltrating cells and the tissue-resident adipocytes leads to 
secretion of adipokines, cytokines, chemokines, and lipids 
with a predominant pro-inflammatory character [3, 8]. 
Moreover, the levels of various adipokines and cytokines are 
altered in obese individuals compared to lean ones (e.g., leptin, 
adiponectin, IL-6). So it seems so that one of therapeutic 
strategies must be directed to normalization of not clinical 
values only but for correction of mentioned molecular 
interplay.  
This cross-talk has also been shown to affect the function of 
adipocytes, such as lipolysis, which will most likely result in 
an altered concentration of circulating free fatty acids. Indeed, 
obese persons have higher levels of free fatty acids in plasma 
compared to lean persons [4-6]. Whether and which of these 
soluble factors (adipokines, cytokines, lipids, etc.) contribute 
to obesity-mediated inflammatory effects in diseases is still 
under investigation. 
Omega-3-polyunsaturated fatty acids are able to inhibit partly 
a number of aspects of inflammation including leucocyte 
chemotaxis, adhesion molecule expression and 
leucocyte‐endothelial adhesive interactions, production of 
eicosanoids like prostaglandins and leukotrienes from the n‐6 
fatty acid arachidonic acid, production of inflammatory 
cytokines and T cell reactivity. Mechanisms underlying the 
anti‐inflammatory actions of n‐3 fatty acids include altered cell 
membrane phospholipid fatty acid composition, disruption of 
lipid rafts, inhibition of activation of the pro‐inflammatory 
transcription factor nuclear factor kappa B so reducing 
expression of inflammatory genes, activation of the 
anti‐inflammatory transcription factor NR1C3 (i.e. peroxisome 
proliferator activated receptor γ) and binding to the G protein 
coupled receptor GPR120. These mechanisms are interlinked 
[3, 4].  
 
5. Conclusions  
Omega-3 fatty acid supplementation has potential of restoring 
of natural balance of adipokines (leptin, adiponectin) and mild 
lipid-lowering action in obese patients with arterial 
hypertension, osteoarthritis and their combination, so, seems to 
be useful in therapeutic patterns for mentioned diseases. Exact 
mechanisms, dosage and longer duration of therapy may be 
promising subject for further investigation. 
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